Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

doi:10.1126/scitranslmed.aao5931

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Science translational medicine - 11 Apr 2018

Tanyi Janos L, Bobisse Sara, Ophir Eran, Tuyaerts Sandra, Roberti Annalisa, Genolet Raphael, Baumgartner Petra, Stevenson Brian J, Iseli Christian, Dangaj Denarda, Czerniecki Brian, Semilietof Aikaterini, Racle Julien, Michel Alexandra, Xenarios Ioannis, Chiang Cheryl, Monos Dimitri S, Torigian Drew A, Nisenbaum Harvey L, Michielin Olivier, June Carl H, Levine Bruce L, Powell Daniel J, Gfeller David, Mick Rosemarie, Dafni Urania, Zoete Vincent, Harari Alexandre, Coukos George, Kandalaft Lana E

Abstract excerpt

We conducted a pilot clinical trial testing a personalized vaccine generated by autologous dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC), which was injected intranodally in platinum-treated, immunotherapy-naïve, recurrent ovarian cancer patients. OCDC was administered alone (cohort 1, n = 5), in combination with bevacizumab (cohort 2, n = 10), or bevacizumab plus low-dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Cancer Vaccines

Share to Cyclophosphamide

Share to Dendritic Cells

Share to Immunotherapy

Share to Ovarian Neoplasms

Share to T-Lymphocytes, Cytotoxic

Source

Open in PubMed

Identifiers

PMID: 29643231
DOI: 10.1126/scitranslmed.aao5931

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.PMID 29643231Read ↗

Personalized vaccines for cancer immunotherapy.Semantic proximity Read ↗

An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors.Semantic proximity Read ↗

Dendritic Cells Immunotherapy of Ovarian Cancer: Overview of Our AchievementsSemantic proximity Read ↗

Immunotherapy for ovarian cancer is improved by tumor-targeted delivery of a neoantigen surrogateSemantic proximity Read ↗

Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.Semantic proximity Read ↗

Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor CellSemantic proximity Read ↗

A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generationSemantic proximity Read ↗

A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.Semantic proximity Read ↗

Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.Semantic proximity Read ↗

Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancerSemantic proximity Read ↗

Tumor RNA-Transfected Dendritic Cells Generated From Induced Pluripotent Stem Cells Induces Anti-Tumor ImmunitySemantic proximity Read ↗

Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.